Search Results

Guardian Research Network, Inc. (GRN) and Cytel Inc. are pleased to announce an upcoming presentation at ISPOR 2022, Washington, DC. ISPOR is the leading professional society for health economics and outcomes research.

The recently announced benefits of fluvoxamine, an inexpensive drug currently approved as an antidepressant, for treating COVID-19, were confirmed thanks to a platform research study, the TOGETHER Trial, which included key design and implementation contributions from Cytel researchers

Nordic Capital and Astorg Invest in Pharmaceutical Technology and Advanced Analytics Company Cytel Cytel is one of the leading global providers of clinical trial design technology, biometric services and advanced analytics, focusing on optimizing clinical trials and helping pharmaceutical companies to unlock the full potential of their clinical and real-world data

Cytel Inc. has launched SolaraTM, a collaborative decision-support platform that revolutionizes the identification of optimal clinical trial designs for greater business results for biotech and pharmaceutical companies.

new paper authored by statistical experts at Cytel has been published in the world-renowned journal CA: A Cancer Journal for Clinicians.

Cytel Inc. has announced that the Complex Innovative Trial Design Symposium and East® Training will take place November 6–7 at Alexion’s headquarters in Boston, Massachusetts.

Cytel Inc. has launched an open-access global COVID-19 Clinical Trial Tracker to help facilitate greater collaboration between researchers, policymakers, clinicians, journalists, philanthropists, and other critical stakeholders who need to understand the complex dynamics of the global response to finding a solution to the COVID-19 outbreak.